MagBICE納米顆粒生產(chǎn)和體外結(jié)合性質(zhì)

雖然干細胞可能是對抗某些疾病的有力武器，但是簡單的用干細胞注入患者體內(nèi)，不能保證干細胞將能夠到達受損部位，并與已經(jīng)存在于那里的細胞協(xié)同合作。

為了將能治愈的干細胞有針對性地傳遞到受傷部位，美國洛杉磯Cedars-Sinai心臟研究所的研究人員用兩種抗體包覆鐵納米粒子，這兩種抗體能夠識別并特異性結(jié)合干細胞，并特異性結(jié)合體內(nèi)的受損細胞。當納米粒子注入到血液之后，它們成功地追蹤到創(chuàng)傷部分并開始治療。

該研究小組負責人、Cedars-Sinai 心臟研究所主任Eduardo Marbán博士說：“該結(jié)果是一種分子對接。通過磁共振成像，我們能夠看到鐵標記的干細胞，到達受損部位并且那里開始愈合。此外，通過在受損心臟上放置一塊磁鐵，可使鐵納米粒子更加接近受損心肌。”

作者認為，鐵納米粒子概念，也可以用來治療其他健康問題，如外周血液疾病和哮喘。Marbán稱，如果未來的研究是成功的，該程序可望在三年之內(nèi)進行人體臨床研究。

原文摘要：

Magnetic antibody-linked nanomatchmakers for therapeutic cell targeting

Ke Cheng, Deliang Shen, M. Taylor Hensley, Ryan Middleton, Baiming Sun, Weixin Liu,Geoffrey De Couto & Eduardo Marbán

Stem cell transplantation is a promising strategy for therapeutic cardiac regeneration, but current therapies are limited by inefficient interaction between potentially beneficial cells (either exogenously transplanted or endogenously recruited) and the injured tissue. Here we apply targeted nanomedicine to achieve in vivo cell-mediated tissue repair, imaging and localized enrichment without cellular transplantation. ?Iron nanoparticles are conjugated with two types of antibodies (one against antigens on therapeutic cells and the other directed at injured cells) to produce magnetic bifunctional cell engager (MagBICE). The antibodies link the therapeutic cells to the injured cells, wheras the ?iron core of MagBICE enables physical enrichment and imaging. We treat acute myocardial infarction by targeting exogenous bone marrow-derived stem cells (expressing ?CD45) or endogenous ?CD34-positive cells to injured cardiomyocytes (expressing myosin light chain. Targeting can be further enhanced by magnetic attraction, leading to augmented functional benefits. MagBICE represents a generalizable platform technology for regenerative medicine.

LONZA細胞培養(yǎng)基產(chǎn)品目錄    網(wǎng)址鏈接 http://www.gducity.com/a/gb2312/product/lonza/xbpy/2010/0928/3757.html

購買進口儀器、試劑和耗材——就在始于2001年的畢特博生物 www.gducity.com